Genetically engineered mouse models (GEMMs) expressing oncogenic KRAS upon Cre recombination, with or without mutation of the tumor suppressor p53, model the development of NSCLC resembling the human disease and are widely used for both basic discovery and preclinical studies (7). This evidence concerns the gene KRAS and non-small cell lung carcinoma.